The current anti-PD medications such as levodopa, dopamine agonist, monoamine oxidase B inhibitors, amantadine, and catechol-O-methyltransferase inhibitors usually possess some defects with low bioavailability (difficult to cross BBB), dopaminergic motor complications and wearing off 44-46. Here, MAOB is linked to Parkinson disease.